Perrigo (PRGO) Depreciation & Amortization (CF) (2013 - 2026)
Perrigo (PRGO) posted quarterly Depreciation & Amortization (CF) of $83.3 million for Q1 2026, up 4.26% year-over-year from $79.9 million in Q1 2025, and down 3.03% quarter-over-quarter from $85.9 million in Q4 2025.
Perrigo (PRGO) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $83.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 4.26% year-over-year to $83.3 million; the TTM figure through Mar 2026 stood at $340.9 million (up 5.09% YoY), while the FY2025 annual figure was $337.5 million, up 3.56% from the prior year.
- Depreciation & Amortization (CF) eased to $83.3 million in Q1 2026 per PRGO's latest filing, from $85.9 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $97.1 million in Q4 2022 and bottomed at $69.5 million in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $85.0 million across 5 years, with a median of $85.4 million in 2025.
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 32.29% in 2022 and fell as far as 23.12% in 2022.
- Perrigo's Depreciation & Amortization (CF) stood at $97.1 million in 2022, then decreased by 11.53% to $85.9 million in 2023, then decreased by 6.52% to $80.3 million in 2024, then grew by 6.97% to $85.9 million in 2025, then retreated by 3.03% to $83.3 million in 2026.
- Business Quant data shows PRGO's Depreciation & Amortization (CF) at $83.3 million in Q1 2026, $85.9 million in Q4 2025, and $85.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Perrigo | 1.98 Bn | 1.58 Bn | 313.90 Mn | 95.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 95.80 Mn |
| Jun 27, 2026 | 95.80 Mn |
| Mar 28, 2026 | 83.30 Mn |
| Mar 28, 2026 | 83.30 Mn |
| Dec 31, 2025 | 85.90 Mn |
| Dec 31, 2025 | 85.90 Mn |
| Sep 27, 2025 | 85.40 Mn |
| Sep 27, 2025 | 85.40 Mn |
| Jun 28, 2025 | 86.30 Mn |
| Jun 28, 2025 | 86.30 Mn |
| Mar 29, 2025 | 79.90 Mn |
| Mar 29, 2025 | 79.90 Mn |
| Dec 31, 2024 | 80.30 Mn |
| Dec 31, 2024 | 80.30 Mn |
| Sep 28, 2024 | 82.30 Mn |
| Sep 28, 2024 | 82.30 Mn |
| Jun 29, 2024 | 81.90 Mn |
| Jun 29, 2024 | 81.90 Mn |
| Mar 30, 2024 | 81.40 Mn |
| Mar 30, 2024 | 81.40 Mn |